The Efficacy Of Fufang Biejia Ruangan Pills Intervention In Portal Hypertension Patients With Liver Cirrhosis

Objective To observe the clinical curative effect and safety of Fufang Biejia Ruangan pills (FFBJRGP) on portal hypertension in patients with liver cirrhosis.Method According to the score of liver function hierarchical, we divided the 98 patients who meet the inclusion criteria into two grade.43 cases in Child-pugh A grade (Group Ⅰ) and 55 cases in Child-pugh B+C grade (Group Ⅱ). Group Ⅰ were divided for FFBJRGP group (test group) 22 cases and blank control group (blank group) 21 cases, group Ⅱ were randomly assigned to compound FFBJRGP combined with propranolol group (combined group) 28 cases, and propranolol group 27 cases, after 24 weeks of treatment, contrast the portal vein diameter, velocity of portal vein and hepatic fibrosis four changes.Results (1) The biochemical indexes:PT value:after treatment, PT value can be improved not only in test group Ⅰ but also in group Ⅱ. In the test group, the curative effect is better than that of blank group, there was significant difference between them (P<0.05); The curative effects were similar in patients of combined group and propranolol group (P>0.05). After treatment, there were significant differences between the test group and the blank group, and the improvement of the four liver fibrosis of the test group was better than that of the blank group (P<0.05), The total effective rates of the two groups were(95.24%,20%); the combined group of HA, PC Ⅲ and Ⅳ-C was better than that of propranolol group (P<0.05), The total effective rates of the two groups were(92.59%,68%).(2) Imaging indexes:group Ⅰ:the improved of portal vein diameter width and portal vein blood flow velocity were positively correlated with the observation time in the test group, there was a remarkable difference in each time period(F=74.62, P<0.01), In the blank group, there was no statistical significance of before and after the treatment (P>0.05). Group Ⅱ:portal vein diameter width, portal blood flow velocity were improved after treatment, and based on the trend chart,we can see that the therapeutic efficacy in the combined group is better than that of propranolol group, but the differences were not significant statistically(The inter-assay variation were F=1.015, P>0.05, F=2.340, P>0.05).Conclusion The curative effect of test group in portal vein and portal vein blood flow velocity is better than the blank group; that were similar in combined group and propranolol group. But in the combined group, the occurrence of propranolol intolerance was less than propranolol group. FFBJRGP has better clinical effect on patients with liver cirrhosis portal vein pressure, safe and stable.